Compare KITT & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITT | RNAZ |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8M | 8.0M |
| IPO Year | N/A | 2021 |
| Metric | KITT | RNAZ |
|---|---|---|
| Price | $1.88 | $7.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 723.8K | 6.5K |
| Earning Date | 04-16-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $6.08 |
| 52 Week High | $6.93 | $20.99 |
| Indicator | KITT | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 27.01 |
| Support Level | $0.76 | $6.08 |
| Resistance Level | $3.53 | $9.37 |
| Average True Range (ATR) | 0.20 | 0.60 |
| MACD | -0.11 | -0.12 |
| Stochastic Oscillator | 2.42 | 3.57 |
Nauticus Robotics Inc is a technology-driven company specializing in the development of fully electric autonomous robotic solutions for subsea applications. Its portfolio includes autonomous underwater vehicles (AUVs), electric robotic manipulators, a platform-agnostic robotic operating system, and related engineering, consulting and prototype services. The Company's solutions enable autonomous operations for both commercial and defense sectors, with alignment to offshore energy and national security interests. Its addressable markets include upstream, midstream and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research and subsea mining, with current focus on oil and gas operations and defense applications.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.